aHUS
Complement – Alternative Pathway (AH50) Functional, Serum
Test
Aliases/Synonyms
Method
ELISA
Method Description
The Wieslab enzyme-linked immunosorbent assay (ELISA) complement assay for the alternative pathway combines principles of the hemolytic assay for complement activation with the use of labeled antibodies specific for neoantigens produced as a result of complement activation. The micro titer plate strips are coated with lipopolysaccharide (LPS). Patient serum is diluted in diluent containing specific blocker to ensure that only the alternative pathway is activated. During the first incubation, the diluted patient serum in the wells is activated by the coating. The wells are then washed and C5b-9 (MAC) is detected with a specific alkaline phosphatase labeled antibody to the neoantigen expressed during MAC formation. After a final wash, an alkaline phosphatase substrate is added. The amount of alternative pathway complement activity correlates with the color intensity of the solution and is measured in terms of absorbance (optical density: OD).(Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA: Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Adv Clin Chem. 2016;77:1-75. doi: 10.1016/bs.acc.2016.06.001)
Report Includes
Complement - Alternative Pathway (AH50) Functional
Specimens
Serum
Clinical Utility
Investigation of suspected alternative pathway complement deficiency, atypical hemolytic uremic syndrome, C3 glomerulonephritis, dense-deposit disease
Test Location
Mayo Clinical Labs, Minnesota USA
Test Version
15-Jan-2021
Specimen
Specimens
Serum
Collection Containers
Red top (no additive). Avoid gel separator tubes.
Sample Volume
1 mL
Minimum Volume
0.2 mL
Specimen Comment
Avoid gel separator tubes
Patient Preparation
Fasting
Collection & Handling
Collection Instructions
Collect a fasting sample.
Handling Information
Immediately after specimen collection, place the tube on wet ice. Centrifuge at 4°C and aliquot serum into plastic vial. Freeze specimen within 30 minutes.
Stability
Frozen | 14 days |
---|
Rejection Criteria
Specimen | Received not frozen |
---|
Test Version
15-Jan-2021
Performance / Interpretation
Method
ELISA
Method Description
The Wieslab enzyme-linked immunosorbent assay (ELISA) complement assay for the alternative pathway combines principles of the hemolytic assay for complement activation with the use of labeled antibodies specific for neoantigens produced as a result of complement activation. The micro titer plate strips are coated with lipopolysaccharide (LPS). Patient serum is diluted in diluent containing specific blocker to ensure that only the alternative pathway is activated. During the first incubation, the diluted patient serum in the wells is activated by the coating. The wells are then washed and C5b-9 (MAC) is detected with a specific alkaline phosphatase labeled antibody to the neoantigen expressed during MAC formation. After a final wash, an alkaline phosphatase substrate is added. The amount of alternative pathway complement activity correlates with the color intensity of the solution and is measured in terms of absorbance (optical density: OD).(Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA: Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Adv Clin Chem. 2016;77:1-75. doi: 10.1016/bs.acc.2016.06.001)
Turnaround Time
12 Days
Results
Name | Units | Reference Range | Conversion Factor | |
---|---|---|---|---|
Complement - Alternative Pathway (AH50) Functional | % of norm |
|
||
Absent complement alternative pathway (AH50) in the presence of a normal total hemolytic complement (CH50) suggests an alternative pathway component deficiency. |
Test Location
Mayo Clinical Labs, Minnesota USA
Test Version
15-Jan-2021
Interface / Setup
HL7 Interface Codes
Order Code | Result Codes | Units |
---|---|---|
AH50F S | 63358Complement, Alternate Path, Func, S | % of norm |
Test Version
15-Jan-2021